DOCSLIB.ORG

Pethidine 50Mg/Ml & 100Mg/2Ml Solution for Injection

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pethidine 50Mg/Ml & 100Mg/2Ml Solution for Injection PACKAGE LEAFLET: INFORMATION FOR THE USER Pethidine Injection must not be used with drugs used to treat TECHNICAL PRESCRIBING INFORMATION Renal impairment may result in accumulation of the potentially severe depression, such as rasagiline or moclobemide, or if you toxic metabolite norpethidine, particularly with repeat dosing. All Pethidine 50mg/ml & 100mg/2ml are within 2 weeks of discontinuing them. Pethidine 50mg/ml & 100mg/2ml of these patient groups may experience increased or prolonged Solution for Injection These drugs are known as Monoamine Oxidase Inhibitors Solution for Injection effects of the product. (MAOI’s), Pethidine should be used with caution in patients with shock, Composition/excipients: Pethidine Hydrochloride Other medicines which may interact with Pethidine Injection hypothyrodism, adreno-corticol insufficiency and a history of Pethidine injection is a sterile aqueous solution of 5% w/v include: convulsive disorders. Read all of this leaflet carefully before you are given this Pethidine Hydrochloride. It also contains Water for Injections and • selegiline, a medicine used to treat Parkinson’s disease Although less spasmogenic than morphine, pethidine may medicine because it contains important information for you. may contain Sodium Hydroxide as a pH adjuster. • Keep this leaflet.You may need to read it again. • ritonavir, a medicine used to treat HIV precipitate spasm of the ureter or Sphincter of Oddi. Subsequently • If you have any further questions, ask your doctor, nurse • cimetidine, a medicine used to treat stomach ulcers Indications: it should be used with caution in patients with prostatic • medicines used to reduce anxiety (anxiolytics) (eg. Relief of moderate to severe pain, as a premedication, obstetric hypertrophy and biliary tract disorders including those with pain D05459 or midwife. • If you get any side effects, talk to your doctor or pharmacist . benzodiazepines such as diazepam) analgesia and enhancement of analgesia. secondary to gallbladder pathology. This includes any possible side effects not listed in this leaflet. • medicines used to help you to sleep (hypnotics) Pethidine should be used with caution in patients with existing See section 4. • CNS depressants (drugs that act on the brain and make you Dose: hypotension as it may reduce the blood pressure further. feel drowsy or faint). These include sleeping pills, Adults. In addition it should be avoided in patients with severe What is in this leaflet anti-histamines (medicines used to treat allergies) that make For moderate or severe pain. inflammatory bowel disease due to its effects on the 1. What Pethidine Injection is and what it is used for you drowsy, medicines used to treat certain mental disorders. Normal single dose (usually not to be repeated more often than 4 gastrointestinal tract where it may precipitate toxic megacolon. 2. Before you are given Pethidine Injection • phenytoin, a medicine used to treat fits hourly) Risk from concomitant use of sedative medicines such as 3. How Pethidine Injection will be given • medicines used to treat serious mental disorders By intramuscular or subcutaneous injection 25 - 100 mg. benzodiazepines or related drugs: 4. Possible side effects (phenothiazines) By slow intravenous injection 25 - 50 mg. Concomitant use of Pethidine and sedative medicines such 5. How to store Pethidine Injection • citalopram, a medicine used to treat depression For obstetric analgesia. as benzodiazepines or related drugs may result in sedation, 6. Contents of the pack and other information • medicines for depression (eg. tricyclic antidepressants such as By intramuscular or subcutaneous respiratory depression, coma and death. Because of these risks, amitriptyline) injection repeated 1 – 3 hours later. 50 - 100 mg. concomitant prescribing with these sedative medicines should 1. What Pethidine Injection is and what it is • sedatives, sleeping tablets or barbiturates (eg. phenobarbitone Maximum of 400mg in 24 hours. be reserved for patients for whom alternative treatment options used for for epilepsy) As a premedication. are not possible. If a decision is made to prescribe Pethidine • domperidone and metoclopramide (used for disorders of the Pethidine is a drug with powerful pain relieving properties. By intramuscular injection one hour prior concomitantly with sedative medicines, the lowest effective dose gastrointestinal tract) to the operation. 50 - 100mg should be used, and the duration of treatment should be as short • pain relievers and other opioid medicines Pethidine Injection is used for the relief of moderate to severe For the enhancement of analgesia. as possible. • ciprofloxacin, an antibiotic used to treat a number of bacterial pain and is used for pain relief during labour. It may also be used By slow intravenous injection. 10 -25mg as required. The patients should be followed closely for signs and symptoms of to stop you from feeling pain before and during an operation and infections Elderly or debilitated patients. respiratory depression and sedation. In this respect, it is strongly to provide continuous pain relief if needed • mexiletine, a medicine used to treat seriously irregular heartbeats Initial doses should not exceed 25mg as this group of patients may recommended to inform patients and their caregivers to be aware be specially sensitive to the central depressant effect of the drug. of these symptoms. 2. Before you are given Pethidine Injection Concomitant use of Pethidine Injection and sedative medicines Children such as benzodiazepines or related drugs increases the risk of You should not be given Pethidine Injection if: For moderate or severe pain. Interactions : drowsiness, difficulties in breathing (respiratory depression), • you are allergic (hypersensitive) to Pethidine Hydrochloride or By intramuscular injection 0.5 - 2 mg per Kg of body weight. Pethidine should not be administered to patients receiving: coma and may be life-threatening. Because of this, concomitant to any of the ingredients of this medicine (listed in section 6) Monoamine Oxidase Inhibitors • you suffer from asthma, shallow breathing or other breathing use should only be considered when other treatment options are As a premedication. The concurrent use of MAOIs (including moclobemide) is contra- difficulties not possible. By intramuscular injection one indicated as they may result in CNS excitation or depression. • you are suffering from severe headaches or have suffered a hour prior to the operation 1 - 2 mg per Kg of body weight. However, if your doctor does prescribe Pethidine together Pethidine should not be administered to patients receiving head injury Method of administration with sedative medicines the dose and duration of concomitant monoamine oxidase inhibitors or moclobemide or within two • you suffer from alcoholism Intramuscular, intravenous or subcutaneous injection. treatment should be limited by your doctor. weeks of their withdrawal. • you suffer from a convulsive disorder (fits) such as epilepsy • you have any liver or kidney problems Please tell your doctor about all sedative medicines you are Contraindications: CNS depressants taking and follow your doctor’s dose recommendation closely. It CNS depressants such as alcohol, hypnotics, anxiolytics and • you are suffering from a condition known as delirium tremens, Hypersensitivity to the active substance or to any of the excipients could be helpful to inform friends or relatives to be aware of the sedatives, barbiturates and tricyclic antidepressants may increase caused by withdrawal from alcohol listed in section 6.1 • your heartbeat is faster than usual signs and symptoms stated above. Contact your doctor when the general depressant effects of pethidine and should therefore experiencing such symptoms. Severe respiratory depression, severe obstructive airways disease be used with caution. • you suffer from a tumour of the adrenal gland known as or acute asthma. phaeochromocytoma Opioid agonists If you are in any doubt please tell your doctor of any medication It should not be administered to patients with severe renal • you suffer from diabetes Additive effects on CNS depression, respiratory depression and you are taking. impairment or severe hepatic impairment. • you are taking or have recently taken any drugs used to treat hypotension can occur with concomitant use of opioid agonist depression known as Monoamine Oxidase Inhibitors (MAOI’s) Pregnancy, breast-feeding and fertility Should be avoided in patients with acute alcoholism, delirium analgesics. (see ‘Taking other medicines) If you are pregnant or breast-feeding, think you may be pregnant tremens, raised intracranial pressure or in those with convulsive MAO-B inhibitors or are planning to have a baby, ask your doctor or pharmacist for states such as status epilepticus. Patients in a coma should not be given this medicine Concomitant use of MAO-B inhibitors such as selegiline or advice before using this medicine. It should not be administered to patients receiving monoamine rasagiline is contraindicated as this may lead to hyperpyrexia Warnings and precautions Pethidine can pass into your baby either through your blood oxidase inhibitors (including moclobemide, and the monoamine and CNS toxicity. Rasagiline should not be given with pethidine Talk to your doctor or pharmacist before being given Pethidine (during pregnancy and labour) or through your breast milk. This B inhibitors selegiline and rasagiline) or within two weeks of their as there is risk of CNS toxicity, its use should
Load more

Recommended publications
  • 2015-02 Toxicology Rapid Testing Panel
    SOUTH CAROLINA LAW ENFORCEMENT DIVISION NIKKI R. HALEY MARK A. KEEL Governor Chief FORENSIC SERVICES LABORATORY CUSTOMER NOTICE 2015-02 REGARDING TOXICOLOGY RAPID TESTING PANEL August 12, 2015 This notice is to inform the Coroners of South Carolina of a new testing panel available through the SLED Toxicology Department. On Monday, August 17th, the Toxicology Department will begin offering both a Rapid Testing Panel in addition to the already available Expanded Testing Panel. This Rapid Testing Panel is to be utilized in cases where the Expanded Testing Panel is not warranted, specifically where a cause of death has already been established. The Rapid Testing Panel will consist of volatiles analysis, to include, ethanol, acetone, isopropanol and methanol, drug screens, and drug confirmation/quantitation of positive screens. The cases assigned to the Rapid Testing Panel will have an expedited turnaround time. Targeted turn around times will be two weeks for negative cases and six weeks or less for positive cases. While every effort will be made to adhere to these time frames, additional time may be required on occasion due to the nature of postmortem samples. Submitters will be notified if there is a problem with a particular sample. Please see attachment regarding specifically which substances are covered by the Rapid Testing Panel and the Expanded Testing Panel. As always, a detailed case history and list of drugs suspected is appreciated. Rapid Panel and Expanded Panel will be choices available in iLAB. Please contact Lt. Dustin Smith (803-896-7385) with additional questions. ALI-359-T An Accredited Law Enforcement Agency P.O.
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Pjp3'2001.Vp:Corelventura
    Copyright © 2001 by Institute of Pharmacology Polish Journal of Pharmacology Polish Academy of Sciences Pol. J. Pharmacol., 2001, 53, 253261 ISSN 1230-6002 INFLUENCE OF DOXEPIN USED IN PREEMPTIVE ANALGESIA ON THE NOCICEPTION IN THE PERIOPERATIVE PERIOD. EXPERIMENTAL AND CLINICAL STUDY Jerzy Wordliczek, Marcin Banach, Magdalena Dorazil, Barbara Przew³ocka*,# Department of Anaesthesiology and Intensive Care, 1st Chair of General Surgery of Collegium Medicum, Jagiellonian University, Kopernika 17, PL 31-501 Kraków, Poland, *Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smêtna 12, PL 31-343 Kraków, Poland Influence of doxepin used in preemptive analgesia on the nociception in the perioperative period. Experimental and clinical study. J. WORDLI- CZEK, M. BANACH, M. DORAZIL, B. PRZEW£OCKA. Pol. J. Pharma- col., 2001, 53, 253–261. The aim of the present research was to assess in experimental and clini- cal study the influence of doxepin administered intraperitoneally (ip) as pre- emptive analgesia on the nociception in the perioperative period. The pain thresholds for mechanical stimuli were measured in rats. The objective of clinical investigation was to assess the influence of preemptive administra- tion of doxepin on postoperative pain intensity, analgesic requirement in the early postoperative period as well as an assessment of the quality of postope- rative analgesia by the patient. Doxepin injected ip (3–30 mg/kg) dose-dependently increased the pain threshold for mechanical stimuli measured in paw pressure test in rats. Do- xepin injected 30 min before formalin significantly increased the nociceptive threshold in the paw pressure test. In contrast, doxepin injected 240 min before formalin or 10 min after formalin did not change the nociceptive threshold.
    [Show full text]
  • A Textbook of Clinical Pharmacology and Therapeutics This Page Intentionally Left Blank a Textbook of Clinical Pharmacology and Therapeutics
    A Textbook of Clinical Pharmacology and Therapeutics This page intentionally left blank A Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK LIONEL D LEWIS MA MB BCH MD FRCP Professor of Medicine, Pharmacology and Toxicology at Dartmouth Medical School and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA TIMOTHY GK MANT BSC FFPM FRCP Senior Medical Advisor, Quintiles, Guy's Drug Research Unit, and Visiting Professor at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK ALBERT FERRO PHD FRCP FBPHARMACOLS Reader in Clinical Pharmacology and Honorary Consultant Physician at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK PART OF HACHETTE LIVRE UK First published in Great Britain in 1981 Second edition 1986 Third edition 1995 Fourth edition 1999 This fifth edition published in Great Britain in 2008 by Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 338 Euston Road, London NW1 3BH http://www.hoddereducation.com ©2008 James M Ritter, Lionel D Lewis, Timothy GK Mant and Albert Ferro All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency.
    [Show full text]
  • Aust Pres 27-2 for Pdfs.Indd
    Does pethidine still have a place in the management of labour pain? Richard W. Watts, Rural General Practitioner, Port Lincoln, South Australia Summary between the median or mean visual analogue pain scores in the pethidine and placebo groups. Pethidine significantly increased Pethidine can provide short-term relief of acute the sedation scores, dizziness, nausea and vomiting.4 pain, but it is not effective for everyone. During labour, intramuscular or intravenous pethidine Comparison with other analgesics sedates women, but may not give them adequate In a randomised controlled trial involving 20 patients in labour, analgesia. Pethidine and its active metabolite, pethidine (up to 1.5 mg/kg) and morphine (up to 0.15 mg/kg) given intravenously produced no significant change in pain norpethidine, can have adverse effects on the scores over time with three doses. Following treatment with neonate as well as the mother, especially if opioids 15 of the patients requested an epidural. Nausea was repeated doses are given during labour. There more common with pethidine (6/10) than with morphine (1/10). is little evidence to show that other drugs have Patients receiving pethidine were calmer and more euphoric, greater efficacy than pethidine, so epidural but both drugs caused similar significant sedation (mean analgesia may be a more effective option. sedation scores 8/10 after three doses). The patients were therefore all significantly sedated and fell asleep during labour, Key words: analgesia, breastfeeding, epidural. but were awakened by pain during contractions. The researchers (Aust Prescr 2004;27:34–5) concluded that labour pain was not sensitive to systemically administered pethidine or morphine and that it was unethical to Introduction treat requests for pain relief by giving sedation.5 Many women prefer to experience birth actively and as naturally Pethidine has also been compared with intravenous fentanyl6, as possible.
    [Show full text]
  • Skeletal Muscle Relaxants Review 12/17/2008
    Skeletal Muscle Relaxants Review 12/17/2008 Copyright © 2007 - 2008 by Provider Synergies, L.L.C. All rights reserved. Printed in the United States of America. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C. All requests for permission should be mailed to: Attention: Copyright Administrator Intellectual Property Department Provider Synergies, L.L.C. 5181 Natorp Blvd., Suite 205 Mason, Ohio 45040 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to
    [Show full text]
  • Urine Drug Tests: How to Make the Most of Them Effective Use of Udts Requires Carefully Interpreting the Results, and Modifying Treatment Accordingly
    Urine drug tests: How to make the most of them Effective use of UDTs requires carefully interpreting the results, and modifying treatment accordingly Xiaofan Li, MD, PhD rine drug tests (UDTs) are useful clinical tools for assessing and Staff Psychiatrist Sioux Falls Veterans Health Care System monitoring the risk of misuse, abuse, and diversion when pre- Assistant Professor scribing controlled substances, or for monitoring abstinence University of South Dakota Sanford School of Medicine U in patients with substance use disorders (SUDs). However, UDTs have Sioux Falls, South Dakota been underutilized, and have been used without systematic documenta- Stephanie Moore, MS tion of reasons and results.1,2 In addition, many clinicians may lack the Toxicologist Richard L. Roudebush VA Medical Center knowledge needed to effectively interpret test results.3,4 Although the Indianapolis, Indiana reported use of UDTs is much higher among clinicians who are mem- Chloe Olson, MD bers of American Society of Addiction Medicine (ASAM), there is still a PGY-4 Psychiatry Resident need for improved education.5 University of South Dakota Sanford School of Medicine Sioux Falls, South Dakota The appropriate use of UDTs strengthens the therapeutic relationship and promotes healthy behaviors and patients’ recovery. On the other hand, incorrect interpretation of test results may lead to missing poten- tial aberrant behaviors, or inappropriate consequences for patients, such Disclosures The authors report no financial relationships with any as discontinuing necessary medications or discharging them from care companies whose products are mentioned in this article, secondary to a perceived violation of a treatment contract due to unex- or with manufacturers of competing products.
    [Show full text]
  • Pain Management in Patients with Substance-Use Disorders
    Pain Management in Patients with Substance-Use Disorders By Valerie Prince, Pharm.D., FAPhA, BCPS Reviewed by Beth A. Sproule, Pharm.D.; Jeffrey T. Sherer, Pharm.D., MPH, BCPS; and Patricia H. Powell, Pharm.D., BCPS Learning Objectives regarding drug interactions with illicit substances or prescribed pain medications. Finally, there are issues 1. Construct a therapeutic plan to overcome barri- ers to effective pain management in a patient with related to the comorbidities of the patient with addic- addiction. tion (e.g., psychiatric disorders or physical concerns 2. Distinguish high-risk patients from low-risk patients related to the addiction) that should influence product regarding use of opioids to manage pain. selection. 3. Design a treatment plan for the management of acute pain in a patient with addiction. Epidemiology 4. Design a pharmacotherapy plan for a patient with Pain is the second most common cause of work- coexisting addiction and chronic noncancer pain. place absenteeism. The prevalence of chronic pain may 5. Design a pain management plan that encompasses be much higher among patients with substance use dis- recommended nonpharmacologic components for orders than among the general population. In the 2006 a patient with a history of substance abuse. National Survey on Drug Use and Health, past-year alco- hol addiction or abuse occurred in 10.3% of men and 5.1% of women. In the same survey, 12.3% of men and Introduction 6.3% of women were reported as having a substance-use Pain, which is one of the most common reasons disorder (abuse or addiction) during the past year.
    [Show full text]
  • COMPASS Therapeutic Notes on the Use of Strong Opioids in Chronic Non-Cancer Pain
    COMPASS Therapeutic Notes on the use of Strong Opioids in Chronic Non-Cancer Pain Glossary of terms In this issue: Hyperalgesic A paradoxical phenomenon whereby a patient receiving treatment for Page syndrome pain may actually become more sensitive to certain painful stimuli Introduction and background 1 MHRA Medicines and Healthcare products Regulatory Agency Strong opioids in common use 2 Neuropathic pain Pain due to disturbance of the nervous system Less commonly used opioids 4 NNT Number Needed to Treat Adverse effects of opioids 4 Nociceptive pain Pain due to tissue damage; can be either somatic or visceral Opioids in specific conditions 6 RCT Randomised controlled trial Opioids and problem drug use 6 SmPC Summary of Product Characteristics Transdermal opioid patches 7 Pain emanating from muscles, skeleton, skin; pain in the parts of the Somatic pain Practical aspects of prescribing 9 body other than the viscera. Visceral pain Pain relating to any of the large interior organs of the body Successful completion of the assessment questions at the end of this issue will provide you with 2 hours towards your CPD/CME requirements. Further copies of this and any other edition in the COMPASS Therapeutic Notes series, including relevant CPD/CME assessment questions, can be found at: www.centralservicesagency.com/display/compass GPs can complete the multiple choice questions on-line and print off their CPD/CME certificate at: www.medicinesni.com Pharmacists can complete the multiple choice questions on-line and print off their CPD certificate at: www.nicpld.org Introduction and background The use of strong opioids in the Table ONE: Classification of opioids management of cancer pain and Approved name palliative care is widely accepted.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME (strength pharmaceutical form) Pethidine, Tablet, 50 mg (PSM) Pethidine, Tablet, 100 mg (PSM) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pethidine Hydrochloride 50 mg Pethidine Hydrochloride 100 mg Excipient(s) with known effect For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral – tablet Presentation Pethidine Hydrochloride 50 mg tablets are: round white normal biconvex tablets, 8.0 mm diameter. Pethidine Hydrochloride 100 mg Tablets are: round white normal biconvex tablets, 9.5 mm diameter. Note: Not all product strengths may be marketed. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Pethidine Tablets given orally are indicated for the relief of most types of moderate to severe pain. As it has some antispasmodic activity, it may be the analgesic of choice in renal colic, biliary colic and acute pancreatitis. 4.2 Dose and method of administration Adults: For the relief of pain, Pethidine Tablets given in oral doses of 50 to 150 mg by mouth every 4 hours if necessary. Children: For the relief of pain, 1.1 to 1.76 mg per kg of body weight, not to exceed 100 mg every 3 to 4 hours as needed. (See Special Warnings and Precautions section 4.4). New Zealand Data Sheet Page 1 of 14 NEW ZEALAND DATA SHEET Opioid agonist analgesics may suppress respiration, especially in the very young, elderly, very ill or debilitated patients and those with respiratory problems. Lower doses may be required for these patients. Neonates (see also Pharmacology section 5 and Use in Pregnancy section 4.6) Excretion and metabolism of Pethidine in the neonate is reduced compared with adults.
    [Show full text]
  • LEGISLATIVE ASSEMBLY Question on Notice
    LEGISLATIVE ASSEMBLY Question On Notice Thursday, 15 February 2018 2560. Ms M. M Quirk to the Minister for Police; I refer to the commencement of operation of the Road Traffic Amendment Act 2016 in March 2017 which introduced compulsory blood or urine samples to be taken from drivers involved in serious crashes, and I ask: (a) since March 2017 how many such samples have been taken; (b) for what specific substances are those blood or urine samples tested; (c) what are the results of those tests to date; and (d) what percentage of drivers have been found to have ingested more than one substance capable of impairing driving skills? Answer (a) The compulsory taking of blood from all drivers involved in serious crashes commenced on 10 March 2017. Between 10 March 2017 and 22 February 2018 (inclusive) a total of 398 blood test samples have been collected under the provision of the Road Traffic Amendment Act 2016. There have been no urine tests collected. (b) Please see attached table for a list of substances in blood sample that are identifiable in ChemCentre toxicology analysis (Paper Number). (c) Of the 398 blood samples collected, 48 are pending results of ChemCentre analysis. Of the 350 analysed, 259 samples had a specific substance(s) detected and 91 samples had no specific substance detected. d) Of the 259 samples with specific substance(s) detected, 92% were found to have multiple substances (more than one). Detectable Substances in Blood Samples capable of identification by the ChemCentre WA. ACETALDEHYDE AMITRIPTYLINE/NORTRIPTYLINE
    [Show full text]